The knee jerk is not unusual in heavily shorted BT's of which CYTK is not, so it is a bit odd. I guessed the move to PIII was giving some BB's the tizzies of an offering to pay for the trials, or some people want in at a lower price. The results look ok after only a single dose. IMHO the bottom line is that those that dumped did so on automatic pilot, or have a longer range plan. I nibbled a bit on the way down, there is no harm as far as I can see.
Stocks that warrant a look in the health care sector include Cytokinetics, Inc. CYTK, Acorda Therapeutics, Inc. ACOR and Affymetrix Inc. AFFX. All of these carry a Zacks Rank #1 (Strong Buy). 2013 they said the same thing and CYTK popped to almost double a little later.
IMHO a buyout is likely and will occur post FDA approval. SGYP has not got a marketing and sales core competency to move forward on commercialization. Likely BP suitors will look to add another drug to their current a GI agent(s) on their in-line Sales portfolio. It us fun to speculate and lots of action prior to that, I wish I waited to buy more at these prices. GLTA
Seen this before, particularily in BT's. I agree with those that think it is a transfer of inexpensive ownership, with help of the lawyers and pulp media help to create FUD. Short Interest has not grown recently, suggesting perhaps they are not loading up. WRT this news, hands may be slapped, issues will be cleared, may be a medium fine or two for maybe going against ethical marketing practices. Be thankfull that all medications do not create any harm and it is not a patient or trial issue. No drugs will be pulled from the market, repeated infringments will create loftier fines in the future. So the appears of cleaner than clean will be the new norm. I just bought back in again. GLTA